ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 13 of 46
УЖМБС 2022, 7(1): 104–111
Clinical Medicine

Characteristics of Laboratory Indicators in Rheumatoid Arthritis Individually and in Combination with Coronary Heart Disease

Ilashchuk T. O., Husarchuk A. G.

The purpose of the study was to analyze the indicators of the lipid spectrum of blood in patients with rheumatoid arthritis individually and in combination with coronary heart disease. Materials and methods. 91 patients with rheumatoid arthritis were examined, which were divided into 2 subgroups – patients with rheumatoid arthritis without concomitant pathology of the cardiovascular system and patients with rheumatoid arthritis with coronary heart disease. The groups were matched in age and gender. The control group consisted of 31 patients with coronary heart disease. When entering the hospital a detailed clinical and biochemical examination with the determination of the pain scale, the number of painful and swollen joints, the duration of the morning stiffness, functional condition, lipid profile of blood was carried out. Results and discussion. In the study of the lipid spectrum of blood, a probable difference between the number of patients with signs of previously undiagnosed hyperlipidemia among patients with rheumatoid arthritis and rheumatoid arthritis with coronary heart disease was detected. At the same time, they observed dependence on the duration of the disease and the age of patients. The most significant changes were detected in the analysis of levels of total cholesterol, high density lipoprotein and low density lipoprotein, atherogenic coefficient. The indicators of blood triglycerides content had only a trend towards an increase in the subgroup of patients with combined nosology, which was not statistically confirmed. The incidence of hypercholesterolemia was 43.4% in the population of patients with rheumatoid arthritis, and 57.6% in patients with rheumatoid arthritis with coronary heart disease. Low density lipoprotein levels exceeded 3.0 mmol/l in 62.7% of rheumatoid arthritis patients and in 81.2% of patients with rheumatoid arthritis with coronary heart disease. The quantitative content of high density lipoprotein less than 1.0 mmol/l was found in 22.9% of patients with rheumatoid arthritis and in 39.6% of patients with rheumatoid arthritis with coronary heart disease. Conclusion. Among patients with rheumatoid arthritis without concomitant cardiovascular disease, and for the combination of rheumatoid arthritis with coronary heart disease, there is a high percentage of patients with hyperlipidemias. Patients with rheumatoid arthritis with concomitant coronary heart disease have reliably higher rates of total cholesterol and low density lipoprotein in the blood, and a reliably lower high density lipoprotein content. The growth of atherogenic coefficient above 3.5 in young and middle-aged patients for the combination of rheumatoid arthritis and coronary heart disease indicates a higher risk of developing cardiovascular disease and their complications in these age groups

Keywords: rheumatoid arthritis, coronary heart disease, cholesterol total, high density lipoprotein, low density lipoprotein, triglycerides

Full text: PDF (Ukr) 343K

  1. Müller R, Kull M, Põlluste K, Aart A, Eglit T, Lember M, et al. The metabolic profile in early rheumatoid arthritis: a high prevalence of metabolic obesity. Rheumatol Int. 2017 Jan;37(1):21-7. PMID: 27084374.
  2. Ma SN, Zaman Huri H, Yahya F. Drug-related problems in patients with rheumatoid arthritis. Ther Clin Risk Manag. 2019;15:505-524. PMID: 30962689. PMCID: PMC6432894.
  3. Agca R, Blanken AB, van Sijl AM, Smulders YM, Voskuyl AE, van der Laken C, et al. Arterial wall inflammation is increased in rheumatoid arthritis compared with osteoarthritis, as a marker of early atherosclerosis. Rheumatology (Oxford). 2021;60(7):3360-3368. PMID: 33447846. PMCID: PMC8516502.
  4. England BR, Thiele GM, Anderson DR, Mikuls TR. Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018;361:k1036. PMID: 29685876. PMCID: PMC6889899.
  5. Krüger K, Nüßlein H. Kardiovaskuläre Komorbiditäten bei rheumatoider Arthritis. Z Rheumatol. 2019;78(3):221-7. PMID: 30656399.
  6. Navarro-Millán I, Yang S, Chen L, Yun H, Jagpal A, Bartels CM, et al. Screening of Hyperlipidemia Among Patients With Rheumatoid Arthritis in the United States. Arthritis Care Res (Hoboken). 2019;71(12):1593-9. PMID: 30414353. PMCID: PMC6510643.
  7. Behl T, Kaur I, Sehgal A, Zengin G, Brisc C, Brisc MC, et al. The Lipid Paradox as a Metabolic Checkpoint and Its Therapeutic Significance in Ameliorating the Associated Cardiovascular Risks in Rheumatoid Arthritis Patients. Int J Mol Sci. 2020;21(24):9505. PMID: 33327502. PMCID: PMC7764917.
  8. Taylor PC, Atzeni F, Balsa A, Gossec L, Müller-Ladner U, Pope J. The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. J Clin Med. 2021;10(3):509. PMID: 33535498. PMCID: PMC7867048.
  9. Zegkos T, Kitas G, Dimitroulas T. Cardiovascular risk in rheumatoid arthritis: assessment, management and next steps. Ther Adv Musculoskelet Dis. 2016;8(3):86-101. PMID: 27247635. PMCID: PMC4872174.
  10. Hammer O, Harper DAT, Ryan PD. PAST: Paleontological Statistics Software Package for Education and Data Analysis. Palaeontologia Electronica. 2001;4(1):9.
  11. Herlitz-Cifuentes H, Vejar C, Flores A, Jara P, Bustos P, Castro I, et al. Plasma from Patients with Rheumatoid Arthritis Reduces Nitric Oxide Synthesis and Induces Reactive Oxygen Species in A Cell-Based Biosensor. Biosensors (Basel). 2019;9(1):32. PMID: 30818887. PMCID: PMC6468433.
  12. Van Dorum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticularbfeature of rheumatoid arthritis? Arthritis Rheum. 2002;46(4):862-73. PMID: 11953961.
  13. Dessie G, Tadesse Y, Demelash B, Genet S. Assessment of Serum Lipid Profiles and High-sensitivity C-reactive Protein Among Patients Suffering from Rheumatoid Arthritis at Tikur Anbessa Specialized Hospital, Addis Ababa, Ethiopia: A Cross-Sectional Study. Open Access Rheumatol. 2020;12:223-232. PMID: 33061690. PMCID: PMC7520147.
  14. Poredoš P, Ježovnik MK. Markers of preclinical atherosclerosis and their clinical relevance. Vasa. 2015;44(4):247-256. PMID: 26314356.
  15. Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460-469. PMID: 19286905.
  16. García-Gómez C, Nolla JM, Valverde J, Gómez-Gerique JA, Castro MJ, Pintó X. Conventional lipid profile and lipoprotein(a) concentrations in treated patients with rheumatoid arthritis. J Rheumatol. 2009;36(7):1365-1370. PMID: 19369465.
  17. Charles-Schoeman C, Lee YY, Grijalva V, Amjadi S, FitzGerald J, Ranganath VK, et al. Cholesterol efflux by high density lipoproteins is impaired in patients with active rheumatoid arthritis. Ann Rheum Dis. 2021;71(7): 1157-1162. PMID: 22267330. PMCID: PMC3428121.
  18. Gomez Rosso L, Lhomme M, Merono T, Sorroche P, Catoggio L, Soriano E, et al. Altered lipidome and antioxidative activity of small, dense HDL in normolipidemic rheumatoid arthritis: relevance of inflammation. Atherosclerosis. 2014;237(2):652-660. PMID: 25463101.
  19. Charles-Schoeman C, Watanabe J, Lee YY, Furst DE, Amjadi S, Elashoff D, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. Arthritis Rheum. 2009;60(10):2870-2879. PMID: 19790070. PMCID: PMC2828490.